

## For Health Professionals Who Care for Cancer Patients

### Inside This Issue:

#### Editor's Choice

##### New Programs

**UGUPAVOABI:** Olaparib with Abiraterone and Prednisone for Prostate Cancer

##### Drug Update

Calaspargase Pegol (ASPARLAS) – New Asparaginase Product

##### Benefit Drug List

**New:** UGUPAVOABI, Calaspargase pegol **Revised:** Denosumab Biosimilar

##### Provincial Systemic Therapy

Systemic Therapy Scheduling Guide

##### Continuing Education

##### Family Practice Oncology Network

Bispecific Antibody Therapy in Cancer Care: What Acute Care Physicians Need to Know for Safe Administration

#### Nursing Update

Learning and Development Update – Bispecific Antibodies

#### NEW Protocols, PPPOs and Patient Handouts

**GU** UGUPAVOABI

#### REVISED Protocols, PPPOs and Patient Handouts

**BR** UBRAJOLA, BRAJPEM, BRAVPEM, BRAVPEM6, BRAVPGC, BRAVPP, BRAVPPN, BRAVSG, BRLACPNAC, BRLACPNACG, BRLACTWAC, BRLACTWACG, BRPCTAC, BRPCWTAC | **GU** UGUPOLAP, GUTIP | **LU** LUAJNIVPC

#### Resources and Contact Information

## Editor's Choice

### New Programs

Effective 01 September 2024, the BC Cancer Provincial Systemic Therapy Program has approved the following new treatment programs. The full details of these programs can be found on the BC Cancer website in the [Chemotherapy Protocols](#) section.

#### Genitourinary

**Olaparib with Abiraterone and predniSONE for Metastatic Castration-Resistant Prostate Cancer (UGUPAVOABI)** – The BC Cancer Genitourinary Tumour Group is introducing olaparib in combination with abiraterone and prednisone as first-line treatment of patients deleterious or suspected deleterious germline and/or somatic BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. In the phase III PROpel study, the addition of olaparib to abiraterone and prednisone was shown to improve radiographic progression-free survival, overall survival, objective response rate, and PSA response rate. Olaparib associated with manageable toxicities consistent with the known safety.[1]

1. CADTH Reimbursement Recommendation. Olaparib (Lynparza): In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before olaparib treatment is initiated. February 2024.

## Drug Update

### Calaspargase Pegol (ASPARLAS) – New Asparaginase Product

Calaspargase Pegol (ASPARLAS) is a new pegylated asparaginase product containing asparaginase from *E. coli*. It has been added to the Benefit List for the same pediatric indications as pegaspargase (ONCASPAR) (see table).

Asparaginase from <i>E. coli</i>	
Pegaspargase (ONCASPAR)	Asparaginase from <i>E. coli</i> attached to polyethylene glycol
Calaspargase pegol (ASPARLAS)	Asparaginase from <i>E. coli</i> attached to monomethoxy-polyethylene glycol
Asparaginase (KIDROLASE)	Asparaginase from <i>E. coli</i> (withdrawn from Canadian market)
Asparaginase from <i>Erwinia chrysanthemi</i>	
Crisantaspase recombinant (RYLAZE)	Recombinant asparaginase identical to asparaginase from <i>Erwinia chrysanthemi</i>
Asparaginase-erwinia (ERWINASE)	Asparaginase from <i>Erwinia chrysanthemi</i> (withdrawn from Canadian market)

## Benefit Drug List

### New Programs

Effective 1 September 2024, the following new treatment programs have been added to the BC Cancer Benefit Drug List:

Protocol Title	Protocol Code	Benefit Status
Treatment for Metastatic Castration-Resistant Prostate Cancer using <b>Olaparib</b> with <b>Abiraterone</b> and <b>predniSONE</b>	<b>UGUPAVOABI</b>	Restricted
<b>Calaspargase pegol</b> as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric patients and young adults aged 1- 21 years	<b>Pediatric</b>	Class I

### Revised Programs

Effective 1 September 2024, denosumab biosimilar WYOST™ has been added the BC Cancer Benefit Drug List.

## Provincial Systemic Therapy

### Systemic Therapy Scheduling Guide

The [Systemic Therapy Scheduling Guide](#) is now posted on the BC Cancer website. This guide is known within BC Cancer as the data dictionary and contains nurse and chair time of systemic therapy treatments. The guide can be found on the [BC Cancer Systemic Therapy](#) webpage for health professionals.

The Systemic Therapy Scheduling Guide is designed to assist healthcare professionals, specifically those working in Community Oncology Sites, determine the appropriate amount of nursing time and chair time required for BC Cancer protocols. The guide is intended for use by clerks, nurses, and other healthcare professionals involved in the scheduling of patients receiving systemic therapy. This guide should be used alongside the protocol, nursing and clinical judgment, and consideration for individual circumstances for each patient's care and treatment schedule. Each health authority and treatment site is welcomed to adopt its use. The goal of this guide is to standardize the care experience provincially by providing the standard time for scheduling patients receiving systemic therapy. These are the scheduling times used by all BC Cancer regional sites.

## Continuing Education

### Bispecific Antibody Therapy in Cancer Care: What Acute Care Physicians Need to Know for Safe Administration

Bispecific Antibody Therapy is rolling out across BC! Co-presented by in-patient general practitioner in oncology (GPO) Dr. Azadeh Arjmandi and hematologist-oncologist Dr. Alina Gerrie, this complimentary webinar will be held **12 September, from 5:30 pm to 7 pm** and is accredited through UBC Continuing Professional Development (CPD) for up to 1.5 Mainpro+ & MOC Section 1 credits. To register, visit this UBC CPD [webpage](#).

Please pass registration information along to acute care physician colleagues in your area including internists, hospitalists, and ER physicians. The learnings are also relevant for GPOs.

## Nursing Update

### Learning and Development Update – Bispecific Antibodies

Bispecific antibodies are a specialized group of Hazardous Drugs that can elicit dramatic host reactions such as cytokine release syndrome (CRS) and related immune effector cell-associated neurotoxicity syndrome (ICANS) requiring monitoring, prompt recognition, and an advanced level of intervention.

To support education and training of nurses who provide care to patients receiving bispecific antibodies, Provincial Professional Practice Nursing has developed a Learning Hub module as an addition to the

## Nursing Update

existing theoretical component of the BC Cancer Systemic Therapy Education Program (STEP). This new module will be incorporated as part of the initial STEP certification process, and nurses who are already ST certified will complete it as a continuing competency requirement.

The module is readily accessible through the Learning Hub: [BC Cancer Bispecific Antibody Education for Nurses](#) and was developed to support all nurses who provide care to patients receiving bispecific antibodies across the province.

In addition, a [Bispecific Antibodies Nursing Resources](#) page, located on the BC Cancer Website, was developed to mirror the current immunotherapy nursing resource section. This page includes the following nursing resources:

- [Bispecific Antibodies Nursing Process](#)
- [SBAR Nursing Handover Tool](#)

Please contact [BCCancerPPNAdmin@phsa.ca](mailto:BCCancerPPNAdmin@phsa.ca) for any queries or concerns.

## List of Revised Protocols, Pre-Printed Orders and Patient Handouts

**BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts** are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

### NEW Protocols, PPPOs and Patient Handouts (*new documents checked* )

Code	Protocol Title	Protocol	PPPO	Handout
UGUPAVOABI	Treatment for Metastatic Castration-Resistant Prostate Cancer using Olaparib with Abiraterone and prednisONE	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--

### REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
<b>BR   Breast</b>				
UBRAJOLA	Treatment of BRCA-Mutated High-Risk Early Breast Cancer using Olaparib	<i>Eligibility clarified</i>	--	--
BRAJPEM	Adjuvant Treatment of Resected Triple Negative Breast Cancer using Pembrolizumab	<i>Eligibility clarified</i>	--	--
BRAVPEM	Treatment of Metastatic Breast Cancer using Pembrolizumab	<i>Eligibility clarified</i>	--	--

## REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Code	Protocol Title	Protocol	PPPO	Handout
<b>BRAVPEM6</b>	Treatment of Metastatic Breast Cancer using 6-Weekly Pembrolizumab	<i>Eligibility clarified</i>	--	--
<b>BRAVPGC</b>	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine, and CARBOplatin	<i>Eligibility clarified</i>	--	--
<b>BRAVPP</b>	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with PACLitaxel	<i>Eligibility clarified</i>	--	--
<b>BRAVPPN</b>	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and PACLitaxel NAB (ABRAXANE)	<i>Eligibility clarified</i>	--	--
<b>BRAVSG</b>	Palliative Therapy for Metastatic Triple Negative Breast Cancer using Sacituzumab Govitecan	<i>Eligibility clarified</i>	--	--
<b>BRLACPNAC</b>	Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	<i>Eligibility clarified</i>	--	--
<b>BRLACPNACG</b>	Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	<i>Eligibility clarified</i>	--	--
<b>BRLACTWAC</b>	NEOAdjuvant Therapy for Triple Negative Breast Cancer Using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	<i>Eligibility clarified</i>	--	--
<b>BRLACTWACG</b>	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	<i>Eligibility clarified</i>	--	--
<b>BRPCTAC</b>	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	<i>Eligibility clarified</i>	--	--
<b>BRPCWTAC</b>	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	<i>Eligibility clarified</i>	--	--
<b>GU   Genitourinary</b>				
<b>UGUPOLAP</b>	Treatment of Metastatic Castration-Resistant Prostate Cancer using Olaparib	<i>Tests clarified, antiemetic risk category and link in footer updated</i>	<i>Tests clarified</i>	--

**REVISED Protocols, PPPOs and Patient Handouts** (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
<b>GUTIP</b>	Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)	--	<i>Reference to Vancouver Centre deleted, hypersensitivity tray added, tests and return appointment orders updated, formatting</i>	--
<b>LU   Lung</b>				
<b>LUAJNIVPC</b>	Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, CARBOplatin and PACLitaxel	<i>Eligibility and exclusions clarified</i>	--	--

## Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update</a>		
Systemic Therapy Update Editor	604-877-6000 x 672649	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Cancer Drug Manual Editor	250-519-5500 x 693742	<a href="mailto:nbadry@bccancer.bc.ca">nbadry@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820	<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
CAP – Compassionate Access Program	604-877-6277	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a> fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a> fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 <a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Library Document Delivery	604-675-8002	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247	<a href="mailto:mlln@bccancer.bc.ca">mlln@bccancer.bc.ca</a>
Professional Practice, Nursing	604-877-6000 x 672623	<a href="mailto:BCcancerPPNAdmin@phsa.ca">BCcancerPPNAdmin@phsa.ca</a>
Provincial Systemic Therapy Program	604-877-6000 x 672247	<a href="mailto:ProvincialSystemicOffice@bccancer.bc.ca">ProvincialSystemicOffice@bccancer.bc.ca</a>
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>		

## Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)  
 Jelena Mucovic, BScPharm (Assistant Editor)  
 Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC  
 Alison Pow, BScPharm  
 Yuna Jang, RN